The Ion Channel That Tells Your Brain When to Stop Scratching

Scratching an itch feels satisfying for a reason. At some point during the act, a signal travels through the nervous system telling the brain that enough has been done - relief has been achieved and the scratching can stop. In people with chronic itch conditions like eczema or psoriasis, this off-switch fails, and scratching continues compulsively, damaging skin and worsening the underlying inflammation in a cycle that can be extraordinarily difficult to break.

Scientists at the University of Louvain in Brussels have now identified a key molecular component of that stop-scratching circuit. In a study presented at the 70th Biophysical Society Annual Meeting in San Francisco in February 2026, Roberta Gualdani and colleagues show that the ion channel TRPV4, when present in sensory neurons, plays a critical role in generating the negative feedback signal that terminates scratching. Remove it, and mice scratch less often - but for much longer each time.

From Pain Research to Itch Biology

TRPV4 belongs to the transient receptor potential family of ion channels, which act as molecular gates in the membranes of sensory neurons, opening in response to physical or chemical stimuli. The channel has been studied in the context of mechanosensation - detecting pressure and tissue stretch - and is known to be expressed in skin cells, where it contributes to itch signaling. Its role specifically in neurons, and particularly in the regulation of itch rather than its generation, had been less clear.

"We were initially studying TRPV4 in the context of pain," said Gualdani. "But instead of a pain phenotype, what emerged very clearly was a disruption of itch - specifically, how scratching behavior is regulated."

To isolate where the channel was acting, the team engineered a genetic mouse model with TRPV4 deleted specifically from sensory neurons, leaving the channel intact in skin and other tissues. Earlier studies had removed TRPV4 from all tissues simultaneously, making it impossible to distinguish neuronal effects from peripheral ones. The neuron-specific deletion avoided that ambiguity.

Fewer Bouts, Longer Duration - A Paradox Explained

The team then induced a chronic itch condition in these mice that resembles atopic dermatitis - the most common form of eczema, affecting roughly 10 to 20 percent of children and 1 to 3 percent of adults worldwide. Compared to normal mice, the TRPV4-deficient animals scratched less frequently. Taken in isolation, this might suggest that removing neuronal TRPV4 reduces itch. But each individual scratching bout lasted substantially longer than in normal mice.

"At first glance, that seems paradoxical," Gualdani said. "But it actually reveals something very important about how itch is regulated."

The interpretation centers on feedback. In normal mice, each scratching bout eventually triggers a TRPV4-dependent signal in mechanosensory neurons - fibers that detect physical touch and pressure. That signal travels to the spinal cord and brain, conveying that the itch site has been mechanically stimulated sufficiently. The scratching stops. In mice without neuronal TRPV4, this feedback signal is absent. Individual bouts of scratching feel perpetually unresolved. The animal eventually stops - but takes far longer to reach that point.

A Dual Role With Therapeutic Implications

The findings point to a functionally important split in what TRPV4 does, depending on where it is expressed. In skin cells, TRPV4 appears to generate itch signals - this is the function that has driven interest in TRPV4 inhibitors as potential treatments for chronic itch. In neurons, the same channel appears to do the opposite: it helps terminate the itch response by signaling that scratching has been adequate.

"This means that broadly blocking TRPV4 may not be the solution," Gualdani noted. "Future therapies may need to be much more targeted - perhaps acting only in the skin, without interfering with the neuronal mechanisms that tell us when to stop scratching."

A drug that blocks TRPV4 everywhere would simultaneously reduce the itch signal from skin and eliminate the stop-scratching feedback from neurons. The net result - fewer but longer scratching bouts - is precisely what was observed in the genetically modified mice. A drug designed this way could actually make chronic itch harder to control in practice, even if it reduced the frequency of scratching episodes.

Open Questions About Chronic Itch

The study used a mouse model of atopic dermatitis, and while mouse itch biology shares many features with human itch biology, the extent to which these specific neuronal TRPV4 findings translate to human chronic itch conditions requires direct investigation. The researchers characterized TRPV4 expression in sensory neuron subtypes using calcium imaging and genetic tools, but a complete circuit-level picture of how the stop-scratching signal travels from peripheral neurons to the spinal cord and brain remains to be worked out.

Chronic itch remains one of the more poorly treated conditions in dermatology. Existing therapies for atopic dermatitis include topical steroids, immunosuppressants, and several newer biological drugs targeting the inflammatory pathways that drive eczema - but none are specifically designed around the neural mechanisms that regulate scratching behavior itself. Identifying TRPV4 in sensory neurons as a component of those mechanisms adds a molecularly defined target to that largely unmapped territory.